AbCellera Biologics Inc. (ABCL)
- Previous Close
2.0100 - Open
2.0500 - Bid 2.0200 x 100
- Ask 2.5900 x 200
- Day's Range
2.0100 - 2.0600 - 52 Week Range
1.8910 - 4.3400 - Volume
3,944,801 - Avg. Volume
4,226,604 - Market Cap (intraday)
605.801M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.71
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
www.abcellera.comRecent News: ABCL
View MorePerformance Overview: ABCL
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABCL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABCL
View MoreValuation Measures
Market Cap
599.83M
Enterprise Value
39.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.52
Price/Book (mrq)
0.57
Enterprise Value/Revenue
1.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.41%
Return on Equity (ttm)
-14.75%
Revenue (ttm)
28.83M
Net Income Avi to Common (ttm)
-162.86M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
625.61M
Total Debt/Equity (mrq)
6.19%
Levered Free Cash Flow (ttm)
-177.77M